Inavolisib or placebo in c,ombination with palbociclib and fulvestrant in patients with PIK3CA-mutated, hormone receptor-positive, HER2-negative locally advanced or metastatic breast cancer: Phase III INAVO120 primary analysis. San Antonio Breast Cancer Symposium; San Antonio, TX: December 5 – 8, 2024; Abstract GS3-13 2023 - Jhaveri, K; Im, S-A; Saura, C